ElectromedELMD -0.37%85 ROC (Joel Greenblatt) % is 55.90% as of Mar. 2026, which is 152% above its 10-year median of 22.22. GuruFocus rates ELMD with a GF Score™ of 85/100 and a GF Value™ of $25.30 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 839 Medical Devices & Instruments companies, Electromed ranks better than 90.11% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Electromed's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 55.90%.
The historical rank and industry rank for Electromed's ROC (Joel Greenblatt) % or its related term are showing as below:
ELMD'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 14.11 Med: 22.22 Max: 51.94
Current: 51.94
During the past 13 years, Electromed's highest ROC (Joel Greenblatt) % was 51.94%. The lowest was 14.11%. And the median was 22.22%.
ELMD's ROC (Joel Greenblatt) % is ranked better than 90.11% of 839
companies
in the Medical Devices & Instruments industry
Industry Median: 3.94
vs ELMD: 51.94
Electromed's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 7.40% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Electromed ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Electromed's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ELMD vs CATX, MASS, CV: ROC (Joel Greenblatt) % Comparison
For the Medical Devices subindustry, Electromed's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Electromed ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Electromed's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Electromed's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 55.90% mean?
Electromed (ELMD) has a ROC (Joel Greenblatt) % of 55.90% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Electromed and its competitors. This is 152% above median its historical median of 22.22. Over the past decade, Electromed's ROC (Joel Greenblatt) % has ranged from 14.11 to 51.94. According to the industry distribution chart, Electromed ranks #83 out of 839 companies in the Medical Devices & Instruments industry, placing it in the top 9.9%.
Is Electromed's ROC (Joel Greenblatt) % too high?
Electromed's current ROC (Joel Greenblatt) % of 55.90% is 152% above median its 10-year median of 22.22. Over the past 10 years, this metric has ranged from a low of 14.11 to a high of 51.94. The Medical Devices & Instruments industry median ROC (Joel Greenblatt) % is 3.94. Electromed's value of 55.90% is 1318.8% above this industry median. Based on the distribution chart, Electromed ranks #83 out of 839 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Electromed has a GF Score™ of 85/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Electromed's ROC (Joel Greenblatt) % compare to CATX and MASS?
According to the Medical Devices & Instruments industry distribution chart, Electromed ranks #83 out of 839 companies for ROC (Joel Greenblatt) %. This places Electromed in the top 10% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 3.94. Electromed's value of 55.90% is 1318.8% above this benchmark. Historically, Electromed's own ROC (Joel Greenblatt) % has ranged from 14.11 to 51.94 over the past decade. While the company's 10-year median is 22.22 vs. the industry median of 3.94, Electromed has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 3.94, based on 839 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Electromed's current ROC (Joel Greenblatt) % of 55.90% is 1318.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Electromed and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 3.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Electromed's current ROC (Joel Greenblatt) % is 55.90%, which is 152% above median its own 10-year median of 22.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Electromed stock overvalued right now?
Based on GuruFocus' analysis, Electromed (ELMD) is currently considered Significantly Overvalued. The stock's GF Value™ is $25.30, compared to a current price of $45.65 — trading 80.4% above its estimated fair value. The current ROC (Joel Greenblatt) % is 55.90%, which is 152% above median its 10-year median of 22.22 and 1318.8% above the Medical Devices & Instruments industry median of 3.94. Electromed's overall GF Score™ is 85/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Electromed (ELMD), the current ROC (Joel Greenblatt) % is 55.90% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Electromed (ELMD) Overvalued in 2026?
Based on GuruFocus' analysis, Electromed stock appears to be overvalued.
The current stock price of $45.65 is trading 80.4% above its estimated GF Value™ of $25.30.
GuruFocus considers Electromed to be Significantly Overvalued.
Key valuation signals for ELMD:
ROC (Joel Greenblatt) %: 55.90% (152% above median its 10-year median of 22.22)
GF Value™: $25.30 vs. price of $45.65 (80.4% above fair value)
Industry Position: 1318.8% above the Medical Devices & Instruments median (#83 of 839)
No single metric tells the full story. See the ELMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Electromed Inc is a United States-based company that develops, manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest Airway Clearance System and related products, to patients with compromised pulmonary function with a commitment to excellence and compassionate service. The SmartVest System features a programmable air pulse generator, a therapy garment worn over the upper body and a connecting hose, which together provide safe, comfortable, and effective airway clearance therapy.
85GF Score
Get the complete analysis for ELMD
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ELMD has been successfully added to your 
